Repligen Co. (NASDAQ:RGEN – Get Rating) – Research analysts at KeyCorp reduced their FY2022 EPS estimates for shares of Repligen in a research note issued to investors on Wednesday, April 27th. KeyCorp analyst P. Knight now anticipates that the biotechnology company will post earnings per share of $3.10 for the year, down from their prior estimate of $3.25. KeyCorp also issued estimates for Repligen’s FY2023 earnings at $3.50 EPS.
Repligen (NASDAQ:RGEN – Get Rating) last released its quarterly earnings results on Wednesday, April 27th. The biotechnology company reported $0.92 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.72 by $0.20. The business had revenue of $206.40 million during the quarter, compared to analyst estimates of $185.48 million. Repligen had a net margin of 19.86% and a return on equity of 11.26%. The company’s quarterly revenue was up 44.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.68 earnings per share.
Shares of Repligen stock opened at $157.24 on Monday. The firm has a market capitalization of $8.56 billion, a P/E ratio of 62.15 and a beta of 0.90. The company has a 50 day moving average price of $173.16 and a 200 day moving average price of $217.42. Repligen has a 52 week low of $138.40 and a 52 week high of $327.32.
In related news, Director Thomas F. Ryan, Jr. sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 1st. The stock was sold at an average price of $198.03, for a total value of $396,060.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.20% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the business. HM Payson & Co. purchased a new stake in Repligen in the fourth quarter valued at approximately $26,000. Confluence Wealth Services Inc. purchased a new stake in Repligen in the fourth quarter valued at approximately $27,000. Assetmark Inc. purchased a new stake in shares of Repligen during the third quarter worth approximately $49,000. Sageworth Trust Co of South Dakota acquired a new position in Repligen during the fourth quarter worth $46,000. Finally, Rise Advisors LLC acquired a new position in Repligen during the fourth quarter worth $52,000. Institutional investors own 86.25% of the company’s stock.
Repligen Company Profile (Get Rating)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
- Get a free copy of the StockNews.com research report on Repligen (RGEN)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- Iridium Communications Stock is Ready to Return to Orbit
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.